EarningsQ2 2026 Earnings Report
MX:BAX Q2 2026 EPS Results
Actual EPS$10.13
Consensus EPS$6.64
Beat/MissBeat by +$3.49
One Year Ago EPS$10.68
MX:BAX Q2 2026 Revenue Results
Actual Revenue$53.56B
Expected Revenue$50.59B
Beat/MissBeat by +$2.98B
YoY Revenue Growth+5.34%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
MX:BAX Upcoming Earnings
Baxter International's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:BAX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed a mostly positive picture: revenue growth was broad-based with Q2 organic sales up 5%, management raised full-year sales and EPS guidance, free cash flow and balance sheet metrics improved, and several product and operational initiatives showed traction (Baxter GPS, PeerVue, Connex 360, Dynamo). However, meaningful near-term headwinds remain — margin pressure from higher-cost inventory and tariffs, ongoing supply constraints (notably in injectables), and the disruption around the Novum IQ LVP platform. The tariff refund was a helpful one-time boost but is nonrecurring. On balance, the company demonstrated tangible operational progress and raised guidance while acknowledging discrete challenges that are being managed.Company Guidance
Top-line growth — Q2 sales up 5%
Second quarter global sales totaled approximately $3.0 billion, increasing 5% on both a reported and organic basis. Growth was broad-based with increases across every segment and in both U.S. and international markets.
Guidance raised — full-year sales and EPS
Company raised full-year reported sales guidance to +3% to +4% (organic sales now expected +2% to +3%). Full-year adjusted EPS guidance was increased by $0.10 to a range of $1.95 to $2.15 per diluted share (up from $1.85 to $2.05), reflecting Q2 performance and a tariff refund.
One-time tariff refund improved near-term results
Baxter received an IEEPA tariff refund of about $75 million in Q2, which contributed approximately $0.11 per diluted share and materially helped Q2 EPS and the decision to raise full-year EPS guidance.
Free cash flow and leverage progress
Second quarter free cash flow was $181 million, improving sequentially; year-to-date free cash flow totaled $257 million. Management reiterated the near-term priority of reducing net leverage to approximately 3x by year-end.
Segment outperformance — Advanced Surgery and Drug Compounding
Advanced Surgery sales were $331 million, up 12% year-over-year. Drug Compounding delivered double-digit growth in Q2 and was called out as a major contributor to the quarter's upside.
Care & Connectivity Solutions (CCS) and HST momentum
Healthcare Systems & Technologies sales were $801 million (+4%); CCS sales totaled $502 million (+5%). Management reported a healthy U.S. order book, solid capital spending to date, strong Connex 360 order growth and an expanding commercial funnel for new products like Dynamo.
Operational execution — Baxter GPS adoption
Baxter's continuous improvement system (Baxter GPS) is being embedded across the company: over 400 continuous improvement events completed, ~200 in flight and another ~400 planned, with early examples of improved efficiency, working capital and simplification.
Product innovation and commercialization progress
Key launches and rollouts include PeerVue (digital benchmarking for infusion therapy), limited market release of Vest APX (airway clearance device) with full release planned by end of Q3, continued adoption of Connex 360, and international expansion of the Dynamo smart stretcher into Canada.
MX:BAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed